Advertisement
"The package of data Trius is presenting at ICAAC provides compelling evidence of the high efficacy of torezolid against difficult to treat bacterial skin infections, including potency against bacterial strains proven to be resistant to linezolid," said Philippe Prokocimer, M.D., chief medical officer at Trius." There is an urgent need for more potent antibiotics like torezolid with different mechanisms of action that can circumvent drug resistance pathways."
Advertisement
ICAAC data presentations are as follows:
Saturday, September 12
(Poster Session 024, 11:30 am - 1:30 pm)
(Poster Session 004, 11:30 am - 1:30 pm)
Sunday, September 13
(Poster Session 082a, 11:15 am - 1:15 pm)
Monday, September 14
(Poster Session 155, 11:15 am - 1:15 pm)
Tuesday, September 15
(Poster Session 226, 9:00 am - 11:00 am)
Copies of these posters will be available on the Trius Web site following the ICAAC meeting.
About Trius Therapeutics
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant, gram-positive bacterial pathogens including those resistant to linezolid, the only currently marketed antibacterial drug of the oxazolidinone class. Trius' pipeline includes two preclinical programs with lead candidates for serious infections caused by gram-negative bacterial pathogens. For more information, visit www.triusrx.com.
-- L1-335/355: Safety and Efficacy of TR-701 in a Phase 2 Randomized, Double-Blind Study in Patients with Severe Complicated Skin and Skin Structure Infections (cSSSI)
SOURCE Trius Therapeutics, Inc.
